- Policy
- Reduction in the scope of platform regulation & re-examinati
- by Lee, Jeong-Hwan Aug 25, 2023 06:06am
- Following the decision to postpone the non-face-to-face treatment institutionalization bill again by the National Assembly Health and Welfare Committee on the 24th, it is evaluated that the number of issues to be resolved for legislation has increased. At the same time, the need to reduce the scope of non-face-to-face treatment patients comp
- Policy
- Verquvo will be listed for reimb at KRW 2,867 in KOR
- by Kim, Jung-Ju Aug 24, 2023 05:46am
- The 3 doses of Bayer Korea’s chronic heart failure treatment Verquvo Tab will be newly listed at KRW 2,867. The price of Abbott Korea’s Depakote Sprinkle Cap (divalproex sodium) will be raised by nearly 22% upon the company’s request and negotiations. According to industry sources on the 22nd, the Ministry of Health and Welfare is worki
- Policy
- Generics for Januvia are deleted from the reimbursement list
- by Lee, Tak-Sun Aug 24, 2023 05:46am
- 6 While 239 drugs containing Sitagliptin, the active ingredient of DPP-4 diabetes treatment Januvia, will be registered for benefit on the 2nd of next month, six existing supplementary items will be deleted from the benefits list. It is interpreted that five items were excluded from the medical care benefit due to the newly created negotiatio
- Policy
- Conflict rise over the need of the PE exemption system
- by Lee, Jeong-Hwan Aug 24, 2023 05:45am
- Experts are showing a sharp conflict of opinion over the effectiveness and need for the existence of Korea's system that exempts new drugs from receiving pharmacoeconomic evaluations. The PE exemption system, which was introduced in 2015, was implemented to improve access to new drugs for patients with severe and rare diseases. However,
- Policy
- 157 single and 82 combo Januvia generics reimbursed in KOR
- by Lee, Tak-Sun Aug 23, 2023 05:46am
- TA total of 239 new drugs that contain ‘sitagliptin,’ the active ingredient of the DPP-4 inhibitor class drug Januvia (MSD), will pour out onto the market on the 2nd of next month. In terms of the number of companies, 59 companies will be releasing their single-agent generics and 63 will be releasing their fixed-combination generics.
- Policy
- 'No other country has a PE exemption system'
- by Lee, Jeong-Hwan Aug 23, 2023 05:46am
- “Korea is the only country that has introduced the use of the pharmacoeconomic evaluation exemption system. As an academic, I do not understand the logic of the PE exemption system. It is also difficult to explain to other countries. If a particular drug has received reimbursement at a non-cost effective price due to the system, it will con
- Policy
- Envlomet SR is priced at 611 won, the same price as Envlo
- by Lee, Tak-Sun Aug 23, 2023 05:46am
- Daewoong Pharmaceutical's self-developed SGLT2i ingredient, Enavogliflozin, combined with Metformin hydrochloride will be released in September. In particular, even though metformin hydrochloride is added, the price is the same as the existing single drug Envlo. This is related to the drug price calculation structure for combination drugs. Ac
- Policy
- Will Pfizer rise to the top with once-weekly growth hormone?
- by Lee, Tak-Sun Aug 22, 2023 05:31am
- A new growth hormone with improved convenience in administration will be introduced to Korea’s annual KRW 240 billion growth hormone market with reimbursement in September this year. The drug is Pfizer's Ngenla Prefilled Pen Inj. Whether Pfizer will use the reimbursement of its new drug as momentum and be able to rise to the top in this
- Policy
- Januvia generics to be listed for reimb on Sept 2nd
- by Lee, Tak-Sun Aug 21, 2023 05:37am
- Competition in the diabetes treatment market is expected to heat up again next month. Following the patent expiry of the SGLT-2 inhibitor class drug Forxiga, which stirred the market in the first half of the year, the patent of Januvia, the leading DPP-4 inhibitor class drug, is set to expire next month. Accordingly, a large number of s
- Policy
- Combination drugs with Januvia to be released in September
- by Lee, Tak-Sun Aug 21, 2023 05:37am
- With the expiry of Januvia's patent on the 1st of next month, the three-drug combination is expected to be launched in earnest in the domestic oral diabetes treatment market. In particular, since the revised reimbursement standard in April recognizes only three drugs, it is noteworthy whether the three-drug complex with improved ease of u
